ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Status:
Active, not recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage
colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to
Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with
recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World
Health Organization (WHO) grade IV malignant gliomas, GBM).
Phase:
Phase 2
Details
Lead Sponsor:
Daniela A. Bota University of California, Irvine
Collaborators:
Epitopoietic Research Corporation University of California, Irvine